Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 5 - 60 |
| Updated: | 6/16/2018 |
| Start Date: | May 16, 2018 |
| End Date: | June 2019 |
| Contact: | Wendy Moore, MPH, CCRP |
| Email: | wendy.moore@childrenscolorado.org |
| Phone: | 720-777-6353 |
The overall goal of the study is to investigate the functional, biochemical, and gene
expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with
Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects
demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of
infections) are the result of biochemical processes and upregulation of specific genes, which
lead to enhanced functionality of this immune cell population.
expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with
Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects
demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of
infections) are the result of biochemical processes and upregulation of specific genes, which
lead to enhanced functionality of this immune cell population.
Inclusion Criteria:
- Current treatment with IFN-γ or intent to treat with this drug
- Acute infections resolved
- Subject is off treatment medications
- Women of childbearing potential must have:
- a negative urine beta-HCG, and
- be willing to practice two forms of effective contraception for the duration of
study participation
Exclusion Criteria:
- Pregnancy,
- Breast-feeding, or
- Unwillingness to use effective contraception
- Recent vaccination (within the last fourteen days)
- Current infection or acute health condition requiring treatment
- Chronic inflammatory complications of CGD including:
- gastric outlet or urinary tract obstruction,
- pleuritis,
- pericarditis,
- inflammatory bowel disease, or
- colitis requiring treatment.
- Un-associated chronic lung, liver, kidney, or cardiac disorders requiring active
treatment
We found this trial at
1
site
13001 E 17th Pl
Aurora, Colorado 80045
Aurora, Colorado 80045
(303) 724-5000
Phone: 303-724-1010
University of Colorado Anschutz Medical Campus Located in the Denver metro area near the Rocky...
Click here to add this to my saved trials
